429 related articles for article (PubMed ID: 29725338)
1. CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
Matsubara N; Imamura A; Yonemizu T; Akatsu C; Yang H; Ueki A; Watanabe N; Abdu-Allah H; Numoto N; Takematsu H; Kitazume S; Tedder TF; Marth JD; Ito N; Ando H; Ishida H; Kiso M; Tsubata T
Front Immunol; 2018; 9():820. PubMed ID: 29725338
[TBL] [Abstract][Full Text] [Related]
2. Sialic Acid Ligand Binding of CD22 and Siglec-G Determines Distinct B Cell Functions but Is Dispensable for B Cell Tolerance Induction.
Özgör L; Meyer SJ; Korn M; Terörde K; Nitschke L
J Immunol; 2018 Oct; 201(7):2107-2116. PubMed ID: 30143587
[TBL] [Abstract][Full Text] [Related]
3. Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.
Spiller F; Nycholat CM; Kikuchi C; Paulson JC; Macauley MS
J Immunol; 2018 Feb; 200(3):949-956. PubMed ID: 29288201
[TBL] [Abstract][Full Text] [Related]
4. B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.
Meyer SJ; Linder AT; Brandl C; Nitschke L
Front Immunol; 2018; 9():2820. PubMed ID: 30559744
[TBL] [Abstract][Full Text] [Related]
5. CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.
Nitschke L
Glycobiology; 2014 Sep; 24(9):807-17. PubMed ID: 25002414
[TBL] [Abstract][Full Text] [Related]
6. Discovery of multifold modified sialosides as human CD22/Siglec-2 ligands with nanomolar activity on B-cells.
Prescher H; Schweizer A; Kuhfeldt E; Nitschke L; Brossmer R
ACS Chem Biol; 2014 Jul; 9(7):1444-50. PubMed ID: 24807582
[TBL] [Abstract][Full Text] [Related]
7. Improved synthesis of CD22-binding sialosides and its application for further development of potent CD22 inhibitors.
Suganuma Y; Imamura A; Ando H; Kiso M; Takematsu H; Tsubata T; Ishida H
Glycoconj J; 2023 Apr; 40(2):225-246. PubMed ID: 36708410
[TBL] [Abstract][Full Text] [Related]
8. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues.
Schweizer A; Wöhner M; Prescher H; Brossmer R; Nitschke L
Eur J Immunol; 2012 Oct; 42(10):2792-802. PubMed ID: 22777817
[TBL] [Abstract][Full Text] [Related]
9. CD22 Controls Germinal Center B Cell Receptor Signaling, Which Influences Plasma Cell and Memory B Cell Output.
Meyer SJ; Steffensen M; Acs A; Weisenburger T; Wadewitz C; Winkler TH; Nitschke L
J Immunol; 2021 Aug; 207(4):1018-1032. PubMed ID: 34330755
[TBL] [Abstract][Full Text] [Related]
10. The Protein Tyrosine Phosphatase SHP-1 (PTPN6) but Not CD45 (PTPRC) Is Essential for the Ligand-Mediated Regulation of CD22 in BCR-Ligated B Cells.
Alborzian Deh Sheikh A; Akatsu C; Abdu-Allah HHM; Suganuma Y; Imamura A; Ando H; Takematsu H; Ishida H; Tsubata T
J Immunol; 2021 Jun; 206(11):2544-2551. PubMed ID: 33990399
[TBL] [Abstract][Full Text] [Related]
11. Proximity labeling of cis-ligands of CD22/Siglec-2 reveals stepwise α2,6 sialic acid-dependent and -independent interactions.
Alborzian Deh Sheikh A; Akatsu C; Imamura A; Abdu-Allah HHM; Takematsu H; Ando H; Ishida H; Tsubata T
Biochem Biophys Res Commun; 2018 Jan; 495(1):854-859. PubMed ID: 29146181
[TBL] [Abstract][Full Text] [Related]
12. Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells.
Enterina JR; Jung J; Macauley MS
Biomed J; 2019 Aug; 42(4):218-232. PubMed ID: 31627864
[TBL] [Abstract][Full Text] [Related]
13. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells.
Collins BE; Blixt O; Han S; Duong B; Li H; Nathan JK; Bovin N; Paulson JC
J Immunol; 2006 Sep; 177(5):2994-3003. PubMed ID: 16920935
[TBL] [Abstract][Full Text] [Related]
14. CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens.
Haas KM; Johnson KL; Phipps JP; Do C
J Immunol; 2018 Mar; 200(5):1671-1681. PubMed ID: 29374074
[TBL] [Abstract][Full Text] [Related]
15. Ligand Recognition Determines the Role of Inhibitory B Cell Co-receptors in the Regulation of B Cell Homeostasis and Autoimmunity.
Tsubata T
Front Immunol; 2018; 9():2276. PubMed ID: 30333834
[TBL] [Abstract][Full Text] [Related]
16. CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling.
Müller J; Obermeier I; Wöhner M; Brandl C; Mrotzek S; Angermüller S; Maity PC; Reth M; Nitschke L
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12402-7. PubMed ID: 23836650
[TBL] [Abstract][Full Text] [Related]
17. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound.
Kelm S; Gerlach J; Brossmer R; Danzer CP; Nitschke L
J Exp Med; 2002 May; 195(9):1207-13. PubMed ID: 11994426
[TBL] [Abstract][Full Text] [Related]
18. The inhibitory coreceptor CD22 restores B cell signaling by developmentally regulating
Akatsu C; Alborzian Deh Sheikh A; Matsubara N; Takematsu H; Schweizer A; Abdu-Allah HHM; Tedder TF; Nitschke L; Ishida H; Tsubata T
Sci Signal; 2022 Mar; 15(723):eabf9570. PubMed ID: 35230871
[TBL] [Abstract][Full Text] [Related]
19. Regulation of B cell development and B cell signalling by CD22 and its ligands alpha2,6-linked sialic acids.
Ghosh S; Bandulet C; Nitschke L
Int Immunol; 2006 Apr; 18(4):603-11. PubMed ID: 16497829
[TBL] [Abstract][Full Text] [Related]
20. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo.
Duong BH; Tian H; Ota T; Completo G; Han S; Vela JL; Ota M; Kubitz M; Bovin N; Paulson JC; Nemazee D
J Exp Med; 2010 Jan; 207(1):173-87. PubMed ID: 20038598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
